Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer

Inclusion Criteria: * Age \>= 18 years * Histological or cytological confirmation of small cell lung cancer * Prior treatment requirements: * Relapsed or progressed after only one prior chemotherapy and PD-1 or PD-L1 inhibitor regimen * Prior therapy must have been an etoposide platinum doublet combined with PD-1 or PD-L1 inhibitor * Group 1: Must have "platinum-sensitive" disease according to the following definitions: * "Sensitive" disease: Relapse occurred \> 90 days after completion of prior therapy * "Resistant" Disease: Relapse occurred =\< 90 days after completion of prior therapy * Group 2: May have "platinum sensitive" (Group 2A) or "platinum resistant" (Group 2B) disease * Measurable disease * Body weight \> 30 kg * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 * Hemoglobin \>= 9.0 g/dL (obtained =\< 15 days prior to registration) * Absolute neutrophil count (ANC) \>= 1500/mm\^3 (obtained =\< 15 days prior to registration) * Platelet count \>= 100,000/mm\^3 (obtained =\< 15 days prior to registration) * Albumin \>= 2.5 mg/dL (obtained =\< 15 days prior to registration) * Total bilirubin =\< 1.5 x upper limit of normal (ULN) or direct bilirubin =\< ULN if total bilirubin is \> 1.5 x ULN (obtained =\< 15 days prior to registration) * Alanine aminotransferase (ALT) and aspartate transaminase (AST) =\< 2.5 x ULN (=\< 5 x ULN for patients with liver involvement) (obtained =\< 15 days prior to registration) * Creatinine OR glo…